id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-333856-ujnhjy0s	Baer, Brandon	Exogenous Surfactant as a Pulmonary Delivery Vehicle for Budesonide In Vivo	2020-10-26		.txt	text/plain	4222	215	40	RESULTS: Although budesonide exhibited anti-inflammatory effects when administered alone, delivery with BLES enhanced those effects by lowering the lavage neutrophil counts and myeloperoxidase activity in lung tissue. Similarly, in vivo studies, including those modeling ARDS, have observed improved drug distribution and anti-inflammatory effects for glucocorticoids delivered by a surfactant vehicle [12] [13] [14] . This study tested the hypothesis that fortifying an exogenous surfactant preparation, BLES, with budesonide would enhance the efficacy for treating pulmonary inflammation in vivo. Specifically, it uses outcomes such as MPO activity, neutrophil counts, and chemokine concentrations to focus on neutrophilic inflammation, which have been suggested to be a critical aspect of disease progression for ARDS [28] When combined with this previous data, our study further supports the use of exogenous surfactant as a delivery vehicle for budesonide in the treatment of pulmonary inflammation.	./cache/cord-333856-ujnhjy0s.txt	./txt/cord-333856-ujnhjy0s.txt